Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of a minority population in breast cancer that integrates into the vasculature and initiates metastasis [scRNA-Seq]

ABSTRACT: Identification of a minority population in breast cancer that integrates into the vasculature and initiates metastasis [scRNA-Seq]

PROVIDER: PRJNA668295 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Identification of a minority population in breast cancer that integrates into the vasculature and initiates metastasis. [RNA-seq]

Project description:Identification of a minority population in breast cancer that integrates into the vasculature and initiates metastasis. [RNA-seq]

| PRJNA668284 | ENA

Identification of a minority population in breast cancer that integrates into the vasculature and initiates metastasis. [RNA-seq]

Project description:Metastasis is responsible for the majority of cancer-related deaths1. Although single-cell RNA sequencing (scRNA-seq) has revealed considerable heterogeneity among tumor cells, identifying the cellular determinants of metastasis has remained challenging. Here, we analyzed scRNA-seq data of primary human breast tumor biopsies and identified a minority population of immature THY1+/VEGFA+ basal epithelial cells that display angiogenic features and are marked by the expression of the oncogene, LMO2. Higher levels of LMO2+ basal cells in human breast tumors correlated with endothelial content and predicted poor distant recurrence-free survival. Using MMTV-PyMT/Lmo2CreERT2 mice, we demonstrate that Lmo2 lineage-traced cells integrate into the vasculature and metastasize to the lung. In human breast tumors, knockdown of LMO2 reduced lung metastasis by affecting multiple steps required for intravasation, leading to a reduced frequency of circulating tumor cells. Mechanistically, we find that LMO2 is a binding partner of STAT3 and is required for STAT3 activation in the presence of the inflammatory cytokines, TNFα and IL6. Collectively, our study identifies a population of metastasis-initiating cells with angiogenic features and establishes the LMO2-STAT3 signaling axis as a therapeutic target in breast cancer metastasis.

2023-10-08 | GSE159282 | GEO

Identification of a minority population in breast cancer that integrates into the vasculature and initiates metastasis [scRNA-Seq]

2023-10-08 | GSE159284 | GEO

Promoting CRC Screening in an Urban Minority Population

Project description:The purpose of this study (Healthy Colon Project II) is to evaluate different educational approaches for increasing rates of colorectal cancer (CRC) screening in a hard-to-reach urban minority population with health insurance.

| 2186033 | ecrin-mdr-crc

Heterogeneity of Breast Cancer Vasculature

Project description:Tumor-associated breast vasculature was laser-cappture microdissected from IDC breast cancer cases. The goal of the study was to characterize the heterogeneity of breast tumor-associated vasculature and identify gene expression signatures predictive of clinical outcome. common reference design, 32 samples

2010-09-19 | E-GEOD-15363 | biostudies-arrayexpress

3D Vasculature-On-A-Chip

Project description:3D Vasculature-On-A-Chip

| PRJNA767611 | ENA

Interaction between BZR1 and PIF4 integrates brassinosteroid and environmental responses

Project description:This SuperSeries is composed of the following subset Series: GSE35315: Interaction between BZR1 and PIF4 integrates brassinosteroid and environmental responses [ChIP-seq] GSE37159: Interaction between BZR1 and PIF4 integrates brassinosteroid and environmental responses [RNA-seq] Refer to individual Series

2012-07-07 | E-GEOD-37160 | biostudies-arrayexpress

Heterogeneity of Breast Cancer Vasculature

2010-09-19 | GSE15363 | GEO

Zebrafish functional xenograft vasculature platform identifies PF-502 as a durable vasculature normalization drug

Project description:Tumor vasculature are structurally chaotic and functionally inefficient. Restoring aberrant tumor blood vessels, or “normalize” the tumor vasculature can alleviate hypoxia and enhance intra-tumoral drug delivery. However, identifying tumor vascular normalizing drugs are currently hampered by an absence of efficient screening platform. We aimed to develop a robust method to visualize, digitalize and evaluate the structural and functional changes of tumor vasculature in batch: zebrafish functional xenograft vasculature platform (zFXVP). As proof of principle, we applied zFXVP to a small compound library which has been implicated in affecting the morphology of tumor vasculature. zFXVP identified PF-502 as a durable tumor vascular normalization agent. Further molecular analysis using RNA-Seq, pharmaceutical inhibition and gene knockout indicate PF-502 can induce endothelial cell cycle arrest and simplify redundant tumor vasculature by blocking PI3K/mTOR signaling and stabilize the vessel lumen and stimulate the blood function by activating Notch1 signaling with mediating S3 cleavage. Last, in mouse tumor xenograft model, PF-502 reproduced a potent vascular normalizing effect at a sub MTD (maximum tolerated dose) and showed its ability to improve intra-tumoral drug delivery and synergize chemotherapy, which confirms the reliability of zFXVP and implicates the potential application of PF-502 in clinical practice as an adjuvant vascular normalization drug.

2023-09-13 | GSE224106 | GEO

Zebrafish functional xenograft vasculature platform identifies PF-502 as a durable vasculature normalization drug

Project description:Zebrafish functional xenograft vasculature platform identifies PF-502 as a durable vasculature normalization drug

| PRJNA929912 | ENA